Review
Aug 2026
Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era
It is argued that PROs should be incorporated as a primary or co-primary endpoint in most modern clinical trials, rather than as a point of interest in exploratory analyses, to better align clinical trial data with patient-centered treatment tolerability.
Elisa N. Hofmeister, A. Major
· Current Hematologic Malignan... · 0 citations